Immune Restoration After Antiretroviral Therapy: The Pitfalls Of Hasty Or Incomplete Repairs

Immunological Reviews

Volumn 254, Issue 1, 2013, Pages 343-354

  Wilson, Eleanor M P ^a   Sereti, Irini ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

AIDS; Cytokines; IRIS; Monocytes macrophages; T cells

Indexed keywords

C REACTIVE PROTEIN; CASPASE 3; CD14 ANTIGEN; CD163 ANTIGEN; CORTICOSTEROID; D DIMER; GAMMA INTERFERON; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 2; INTERLEUKIN 6; KI 67 ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NATALIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; RANTES; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ANTIMICROBIAL THERAPY; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNITY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DEATH; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; CYTOMEGALOVIRUS; DENDRITIC CELL; FIBRINOLYSIS; HERPES SIMPLEX VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INNATE IMMUNITY; INTESTINE LYMPHATIC TISSUE; KAPOSI SARCOMA; LIMIT OF DETECTION; LIVER FIBROSIS; LONG TERM CARE; MACROPHAGE ACTIVATION; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NATURAL KILLER CELL; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN TARGETING; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TUBERCULOSIS; VIROTHERAPY; VIRUS HEPATITIS; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFLAMMATION;

EID: 84879317212     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12064     Document Type: Article

References (131)

1. Autran B, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
2. Palella FJ Jr., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
3. Nakagawa F, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012;26:335-343.
4. Robbins GK, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009;48:350-361.
5. Valdez H, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002;16:1859-1866.
6. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007;44:441-446.
7. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009;338:a3172.
8. Guaraldi G, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011;53:1120-1126.
9. Barber DL, Andrade BB, Sereti I, Sher A. Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat Rev Microbiol 2012;10:150-156.
10. French MA. Immune reconstitution inflammatory syndrome: immune restoration disease 20 years on. Med J Australia 2012;196:318-321.
11. Shelburne SA, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005;19:399-406.
12. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006;42:418-427.
13. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010;10:251-261.
14. Naidoo K, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Int Med 2012;157:313-324.
15. Marais S, Wilkinson RJ, Pepper DJ, Meintjes G. Management of patients with the immune reconstitution inflammatory syndrome. Curr HIV/AIDS Rep 2009;6:162-171.
16. Barber DL, et al. Th1-driven immune reconstitution disease in Mycobacterium avium-infected mice. Blood 2010;116:3485-3493.
17. Bower M, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005;23:5224-5228.
18. Calabrese LH, Kirchner E, Shrestha R. Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. Semin Arthritis Rheum 2005;35:166-174.
19. Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008;22:601-610.
20. Honig M, Schwarz K. Omenn syndrome: a lack of tolerance on the background of deficient lymphocyte development and maturation. Curr Opin Rheumatol 2006;18:383-388.
21. Antonelli LR, et al. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood 2010;116:3818-3827.
22. Mahnke YD, et al. Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood 2012;119:3105-3112.
23. Chahroudi A, Silvestri G. IRIS: the unfortunate rainbow of HIV. Blood 2012;119:2971-2972.
24. Sereti I, Rodger AJ, French MA. Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis. Current opinion in HIV and AIDS 2010;5:504-510.
25. Bonham S, Meya DB, Bohjanen PR, Boulware DR. Biomarkers of HIV Immune Reconstitution Inflammatory Syndrome. Biomark Med 2008;2:349-361.
26. Grant PM, et al. Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164. J Infect Dis 2012;206:1715-1723.
27. Tadokera R, et al. The role of interleukin-10 family of cytokines in HIV-tuberculosis associated immune reconstitution inflammatory syndrome. J Infect Dis 2013;207:1148-1156.
28. Oldenhove G, et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 2009;31:772-786.
29. Nyirenda MH, et al. TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. J Immunol 2011;187:2278-2290.
30. Franceschini D, et al. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest 2009;119:551-564.
31. Behrens F, et al. Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritis. Ann Rheum Dis 2007;66:1151-1156.
32. Boulware DR, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med 2010;7:e1000384.
33. Pean P, et al. Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis. Blood 2012;119:3315-3320.
34. Frleta D, et al. HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. J Clin Invest 2012;122:4685-4697.
35. Lorch JM, et al. Experimental infection of bats with Geomyces destructans causes white-nose syndrome. Nature 2011;480:376-378.
36. Meteyer CU, Barber D, Mandl JN. Pathology in euthermic bats with white nose syndrome suggests a natural manifestation of immune reconstitution inflammatory syndrome. Virulence 2012;3:583-588.
37. Kaufmann GR, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Int Med 2003;163:2187-2195.
38. Lapadula G, et al. Risk of clinical progression among patients with immunological non response despite virological suppression after combination antiretroviral treatment. AIDS 2013;27:769-779.
39. Tan R, et al. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008;47:553-558.
40. Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002;16:359-367.
41. Kaufmann GR, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005;41:361-372.
42. Greub G, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000;356:1800-1805.
43. Almeida M, Cordero M, Almeida J, Orfao A. Abnormal cytokine production by circulating monocytes and dendritic cells of myeloid origin in ART-treated HIV-1+ patients relates to CD4+ T-cell recovery and HCV co-infection. Curr HIV Res 2007;5:325-336.
44. Guihot A, Bourgarit A, Carcelain G, Autran B. Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol 2011;32:131-137.
45. Hu H, et al. Distinct gene expression profiles associated with the susceptibility of pathogen-specific CD4 T cells to HIV-1 infection. Blood 2013;121:1136-1144.
46. Schacker TW, et al. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest 2002;110:1133-1139.
47. Zeng M, Haase AT, Schacker TW. Lymphoid tissue structure and HIV-1 infection: life or death for T cells. Trends Immunol 2012;33:306-314.
48. Pakker NG, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998;4:208-214.
49. Yin L, Kou ZC, Rodriguez C, Hou W, Goodenow MM, Sleasman JW. Antiretroviral therapy restores diversity in the T-cell receptor Vbeta repertoire of CD4 T-cell subpopulations among human immunodeficiency virus type 1-infected children and adolescents. Clin Vaccine Immunol 2009;16:1293-1301.
50. Ciccone EJ, et al. CD4+ T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1-infected long-term nonprogressors. J Virol 2011;85:5880-5888.
51. Ciccone EJ, et al. Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels. Mucosal Immunol 2010;3:172-181.
52. Camargo JF, et al. Responsiveness of T cells to interleukin-7 is associated with higher CD4+ T cell counts in HIV-1-positive individuals with highly active antiretroviral therapy-induced viral load suppression. J Infect Dis 2009;199:1872-1882.
53. Catalfamo M, et al. HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci USA 2008;105:19851-19856.
54. Hodge JN, et al. Decreases in IL-7 levels during antiretroviral treatment of HIV infection suggest a primary mechanism of receptor-mediated clearance. Blood 2011;118:3244-3253.
55. Zeng M, et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 2011;121:998-1008.
56. Tabb B, et al. Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving anti-tumor necrosis factor treatment during primary simian immunodeficiency virus infection. J Infect Dis 2013;207:880-892.
57. Estes J, et al. Collagen deposition limits immune reconstitution in the gut. J Infect Dis 2008;198:456-464.
58. Read SW, Sereti I. HIV infection and the gut: scarred for life? J Infect Dis 2008;198:453-455.
59. Anthony KB, et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr 2003;33:125-133.
60. Boasso A, Shearer GM. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol 2008;126:235-242.
61. French MA, King MS, Tschampa JM, da Silva BA, Landay AL. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis 2009;200:1212-1215.
62. Baker JV, et al. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2011;56:36-43.
63. Kuller LH, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5:e203.
64. Duprez DA, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS ONE 2012;7:e44454.
65. Musselwhite LW, et al. Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV. AIDS 2011;25:787-795.
66. Palmer S, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003;41:4531-4536.
67. Piwowar-Manning EM, Henderson TA, Brisbin L, Jackson JB. A modified ultrasensitive assay to detect quantified HIV-1 RNA of fewer than 50 copies per milliliter. Am J Clin Pathol 2003;120:268-270.
68. Gandhi RT, et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2012;59:229-235.
69. Chege D, et al. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial. AIDS 2012;26:167-174.
70. Llibre JM, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther 2012;17:355-364.
71. Mens H, et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol 2010;84:12971-12981.
72. Pereyra F, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 2012;26:2409-2412.
73. Hunt PW, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008;197:126-133.
74. Taiwo B, Barcena L, Tressler R. Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy. Curr HIV/AIDS Rep 2013;10:21-32.
75. Quesnel A, et al. Antibodies to Epstein-Barr virus and cytomegalovirus in relation to CD4 cell number in human immunodeficiency virus 1 infection. J Med Virol 1992;36:60-64.
76. Sacre K, et al. A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. AIDS 2012;26:805-814.
77. Parrinello CM, et al. Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. J Infect Dis 2012;205:1788-1796.
78. Hunt PW, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis 2011;203:1474-1483.
79. Nagot N, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007;356:790-799.
80. Roxby AC, et al. Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2. PLoS ONE 2012;7:e38622.
81. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol 2013;21:6-13.
82. Brenchley JM, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371.
83. Mehandru S, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004;200:761-770.
84. Mavigner M, et al. Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest 2012;122:62-69.
85. Hayes TL, et al. Impact of highly active antiretroviral therapy initiation on CD4+ T-cell repopulation in duodenal and rectal mucosa. AIDS 2013;27:867-877.
86. Gordon SN, et al. Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J Immunol 2007;179:3026-3034.
87. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003;21:265-304.
88. Doitsh G, et al. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 2010;143:789-801.
89. Murooka TT, et al. HIV-infected T cells are migratory vehicles for viral dissemination. Nature 2012;490:283-287.
90. Klatt NR, Brenchley JM. Th17 cell dynamics in HIV infection. Curr Opin HIV AIDS 2010;5:135-140.
91. Andersson J, et al. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol 2005;174:3143-3147.
92. Mozos A, et al. Redistribution of FOXP3-positive regulatory T cells from lymphoid tissues to peripheral blood in HIV-infected patients. J Acquir Immune Defic Syndr 2007;46:529-537.
93. Oswald-Richter K, et al. HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol 2004;2:E198.
94. Xing S, et al. Increased turnover of FoxP3high regulatory T cells is associated with hyperactivation and disease progression of chronic HIV-1 infection. J Acquir Immune Defic Syndr 2010;54:455-462.
95. Favre D, et al. Tryptophan catabolism by indoleamine 2, 3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010;2:32ra36.
96. Favre D, et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog 2009;5:e1000295.
97. Lindqvist M, et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest 2012;122:3271-3280.
98. Petrovas C, et al. CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest 2012;122:3281-3294.
99. Gattinoni L, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011;17:1290-1297.
100. Bosinger SE, Sodora DL, Silvestri G. Generalized immune activation and innate immune responses in simian immunodeficiency virus infection. Current opinion in HIV and AIDS 2011;6:411-418.
101. Mandl JN, et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med 2008;14:1077-1087.
102. Harris LD, et al. Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection of rhesus macaques. J Virol 2010;84:7886-7891.
103. Bosinger SE, et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest 2009;119:3556-3572.
104. Jacquelin B, et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 2009;119:3544-3555.
105. O'Brien M, et al. Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-alpha-producing and partially matured phenotype. J Clin Invest 2011;121:1088-1101.
106. Baker J, et al. Monocyte Activation, but Not T-cell Activation, Predicts Progression of Coronary Artery Calcium in a Contemporary HIV Cohort. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, USA: CROI, LLC, 2013.
107. Singh A, et al. Plasma Levels of IL-6, D-dimer, and CRP in HIV positive Adults are Associated with Monocyte Activation. Keystone Symposia: Immune Activation in HIV Infection. Breckenridge, CO, USA, 2013.
108. Funderburg NT, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 2010;115:161-167.
109. Mayne E, et al. Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr 2012;59:340-346.
110. Hearps AC, et al. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS 2012;26:843-853.
111. Ford ES, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010;24:1509-1517.
112. Ananworanich J, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS ONE 2012;7:e33948.
113. Evering TH, et al. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog 2012;8:e1002506.
114. Sáez-Cirión A, et al. Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. PLoS Pathog 2013;9:e1003211.
115. Le T, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013;368:218-230.
116. Kovacs JA, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996;335:1350-1356.
117. Davey RT, Jr, et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA 2000;284:183-189.
118. Abrams D, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009;361:1548-1559.
119. Levy Y, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009;119:997-1007.
120. Sereti I, et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009;113:6304-6314.
121. Cimbro R, et al. IL-7 induces expression and activation of integrin alpha4beta7 promoting naive T-cell homing to the intestinal mucosa. Blood 2012;120:2610-2619.
122. Levy Y, et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012;55:291-300.
123. Camargo JF, et al. CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J Immunol 2009;182:171-182.
124. Rossi R, et al. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin Exp Immunol 2011;166:184-190.
125. Wilkin TJ, et al. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4(+) T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis 2012;206:534-542.
126. Gutierrez C, et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS ONE 2011;6:e27864.
127. Lichtenstein KA, et al. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses. Antivir Ther 2012;17:1301-1309.
128. Deeks SG. HIV infection, lymphoid fibrosis, and disease. Blood 2012;120:1753-1754.
129. Zeng M, et al. Critical role of CD4 T cells in maintaining lymphoid tissue structure for immune cell homeostasis and reconstitution. Blood 2012;120:1856-1867.
130. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-1177.
131. Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS ONE 2011;6:e21843.